Search Results - "CATIMEL, G"

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer by Nabholtz, J M, Gelmon, K, Bontenbal, M, Spielmann, M, Catimel, G, Conte, P, Klaassen, U, Namer, M, Bonneterre, J, Fumoleau, P, Winograd, B

“…The objective of this multicenter study was to compare the therapeutic index of two different doses of paclitaxel given as a 3-hour infusion in patients with…”
Get more information

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials by Bachelot, T., Ray-Coquard, I., Catimel, G., Ardiet, C., Guastalla, J. P., Dumortier, A., Chauvin, F., Droz, J. P., Philip, T., Clavel, M.

“…Background: Patients with advanced solid tumors may be included in phase I clinical trials. In such studies, the benefit expected is generally lower than the…”
Get full text

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer by Planting, A. S. T., Catimel, G., de Mulder, P. H. M., de Graeff, A., Höppener, F., Verweij, I., Oster, W., Vermorken, J. B.

“…Background: Cisplatin is one of the most active cytotoxic agents available for the treatment of patients with head and neck cancer. In a previous phase II…”
Get full text

Docetaxel and cisplatin : An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck: Results of a phase II study of the EORTC Early Clinical Studies Group by SCHÖFFSKI, P, CATIMEL, G, PLANTING, A. S. T, DROZ, J.-P, VERWEIJ, J, SCHRIJVERS, D, GRAS, L, SCHRIJVERS, A, WANDERS, J, HANAUSKE, A. R

“…Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found the combination of the two drugs to be…”
Get full text

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study by Wagener, D J, Verdonk, H E, Dirix, L Y, Catimel, G, Siegenthaler, P, Buitenhuis, M, Mathieu-Boué, A, Verweij, J

“…CPT-11 (irinotecan) is a semi-synthetic derivative of camptothecin and exerts its activity by inhibiting DNA topoisomerase I. A phase II study of this drug was…”
Get more information

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials by Chabot, G G, Abigerges, D, Catimel, G, Culine, S, de Forni, M, Extra, J M, Mahjoubi, M, Hérait, P, Armand, J P, Bugat, R

“…Irinotecan (CPT-11) is a novel water-soluble camptothecin derivative selected for clinical testing based on its good in vitro and in vivo activity in various…”
Get more information

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study by Merrouche, Y, Extra, J M, Abigerges, D, Bugat, R, Catimel, G, Suc, E, Marty, M, Hérait, P, Mahjoubi, M, Armand, J P

“…To assess, on a multicenter basis, the feasibility of treating advanced cancer patients with high-dose irinotecan. Thirty-five patients who met the usual phase…”
Get more information

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors by GIACCONE, G, LINN, S. C, WELINK, J, CATIMEL, G, STIELTJES, H, VAN DER VIJGH, W. J. F, EELTINK, C, VERMORKEN, J. B, PINEDO, H. M

“…Forty-two patients with advanced solid tumors were entered into a dose-finding study of the combination of doxorubicin with the cyclosporin analogue SDZ PSC…”
Get full text

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors by Catimel, G, Chabot, G G, Guastalla, J P, Dumortier, A, Cote, C, Engel, C, Gouyette, A, Mathieu-Boué, A, Mahjoubi, M, Clavel, M

“…We conducted a phase I and pharmacokinetic study to determine the maximum tolerable dose (MTD), toxicities, pharmacokinetic profile, and antitumor activity of…”
Get more information

Breast cancer: chemotherapy in the treatment of advanced disease by Clavel, M, Catimel, G

“…Chemotherapy in patients with advanced breast cancer remains palliative. Although the majority of patients will experience an initial response or stabilisation…”
Get more information

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies by Armand, J. P., Extra, Y. M., Catimel, G., Abigerges, D., Marty, M., Clavel, M.

“…Background: CPT-11 (irinotecan), a camptothecin-derived anticancer agent with DNA topoisomerase 1 inhibitory activity, has demonstrated a broad spectrum of in…”
Get full text

Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a by Zenone, T, Catimel, G, Barbet, N, Clavel, M

Get more information

Phase II studies of docetaxel in the treatment of various solid tumours by Verweij, J., Catimel, G., Sulkes, A., Sternberg, C., Wolff, I., Aamdal, S., van Hoesel, Q.

“…Docetaxel has been evaluated in six tumour types in a total of 189 patients entered into phase II studies. Treatment consisted of a 1 h intravenous infusion of…”
Get full text

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy by CHEVALLIER, B, CAPPELAERE, P, CLAVERIE, N, SPLINTER, T, FABBRO, M, WENDLING, J. L, CALS, L, CATIMEL, G, GIOVANNINI, M, KHAYAT, D, BASTIT, P

“…The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting…”
Get full text

Phase II clinical trials with rhizoxin in breast cancer and melanoma by HANAUSKE, A.-R, CATIMEL, G, AAMDAL, S, TEN BOKKEL HUININK, W, PARIDAENS, R, PAVLIDIS, N, KAYE, S. B, TE VELDE, A, WANDERS, J, VERWEIJ, J

Get full text

KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study by Schrijvers, D, Catimel, G, Highley, M, Höppener, F J, Dirix, L, De Bruijn, E, Droz, J P, Van Oosterom, A T

“…KW-2149 is a new, semisynthetic, C-7-N-Substituted, mitomycin C analog showing antitumor activity both in vitro and in vivo, equal or superior to mitomycin C…”
Get more information

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety by Catimel, G, Spielmann, M, Dieras, V, Kayitalire, L, Pouillart, P, Guastalla, J P, Soler-Michel, P, Graffand, N, Garet, F, Dumortier, A, Pellae-Cosset, B, Chazard, M

“…Attempting to develop a new active, convenient regimen, we initiated a phase I study of paclitaxel (Taxol; Bristol-Myers squibb Company, Princeton, NJ)…”
Get more information

Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma by Froudarakis, M E, Catimel, G, Guastalla, J P, Rebattu, P, Clavel, M

Get more information

Phase II study of rhizoxin in squamous cell head and neck cancer by VERWEIJ, J, WANDERS, J, GIL, T, SCHÖFFSKI, P, CATIMEL, G, TE VELDE, A, DE MULDER, P. H. M

Get full text

Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology? by Merrouche, Y, Catimel, G, Clavel, M

Get more information